<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162622">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981435</url>
  </required_header>
  <id_info>
    <org_study_id>20081142</org_study_id>
    <nct_id>NCT00981435</nct_id>
  </id_info>
  <brief_title>Steroids After Laser Trabeculoplasty for Glaucoma</brief_title>
  <acronym>SALT</acronym>
  <official_title>Steroids And Laser Trabeculoplasty (SALT) Trial: Effect of Anti-Inflammatory Treatment on the Efficacy of SLT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bascom Palmer Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the choice of post-operative eye drop
      administered after selective laser trabeculoplasty (SLT) for glaucoma affects the efficacy
      in lowering intraocular pressure (IOP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SLT is used to lower intraocular pressure in glaucoma, but it is not know whether the choice
      of eyedrops administered in the post-operative period affects SLT efficacy. Practitioners
      commonly use steroid drops, non-steroidal anti-inflammatory drops, or no drops at all. This
      is a randomized, single-center, prospective, masked clinical trial to determine whether the
      choice of eyedrop affects efficacy of SLT in glaucoma patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP) lowering</measure>
    <time_frame>6-12 weeks</time_frame>
    <description>IOP will be measured before and at 6 and 12 weeks after intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular inflammation</measure>
    <time_frame>1-12 weeks</time_frame>
    <description>The number of patients with persistent inflammation will be measured in each study arm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Artificial Tears</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-steroidal anti-inflammatory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone 1%</intervention_name>
    <description>Prednisolone 1% to lasered eye 4 times/day for 4.5 days</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac 0.1%</intervention_name>
    <description>Diclofenac sodium 0.1% to lasered eye 4 times/day for 4.5 days</description>
    <arm_group_label>Non-steroidal anti-inflammatory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial Tears</intervention_name>
    <description>Artificial saline tears to lasered eye 4 times/day for 4.5 days</description>
    <arm_group_label>Artificial Tears</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of glaucoma

          -  clinician has determined that SLT laser is indicated

          -  IOP currently &gt;18 and was ever &gt;21 in the past (e.g. prior to treatment)

        Exclusion Criteria:

          -  prior history of uveitis

          -  prior glaucoma surgery including glaucoma laser surgery

          -  pregnant or 3 months post-partum
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 1, 2016</lastchanged_date>
  <firstreceived_date>September 21, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Jeffrey L Goldberg</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Trabeculoplasty</keyword>
  <keyword>Selective laser trabeculoplasty</keyword>
  <keyword>Intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
